|Bid||69.01 x 800|
|Ask||71.00 x 800|
|Day's Range||68.10 - 72.65|
|52 Week Range||27.04 - 106.58|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||81.75|
Guardant Health, Inc. (GH), announced that the positive results from the NILE study, a head-to-head comparison of the Guardant360® assay to standard-of-care tissue testing for the identification of guideline-recommended biomarkers in first-line advanced non-small cell lung cancer (NSCLC) patients, have been published in Clinical Cancer Research1. The landmark study adds new data regarding Guardant360’s high concordance to tissue testing to the abstract that was highlighted before the AACR Annual Meeting and presented by the study’s senior author Vassiliki Papadimitrakopoulou, MD, Chief Section of Thoracic Medical Oncology, MD Anderson Cancer Center. The study adds to a growing body of literature2,3 demonstrating that using Guardant360 first for genomic biomarker detection in advanced NSCLC can increase the number of patients tested for guideline-recommended biomarkers.
Stocks that moved substantially or traded heavily on Wednesday: JetBlue Airways Corp., up 58 cents to $16.92 The airline reported a 7.9% increase in air traffic in March, along with an increase in flight ...
While se Bruin says Guardant shares are admittedly expensive after its recent rally, the company’s massive growth potential has skewed the risk decidedly to the upside. De Bruin has been hesitant to get behind such a volatile stock with a steep valuation, but several factors have improved the stock’s outlook in recent weeks. First, Guardant’s LUNAR-1 data at the American Association of Cancer Research meeting was positive.
Growth stocks led an early rally. Wednesday. Delta Air Lines rose on earnings. Levi Strauss and hot IPO stock Guardant Health jumped. Apple got a sell rating.
Guardant Health, Inc. (GH), announced that its market leading liquid biopsy, Guardant360®, will be a covered benefit for the members of the health plans associated with eviCore, a technology assessment company. The test will be considered medically necessary to assist in selecting therapy for patients with advanced lung cancer. When the eviCore policy becomes effective July 1, Guardant360 will have added coverage for over 38 million lives in 2019, including with Health Care Service Corporation in Illinois, Montana, New Mexico, Oklahoma, and Texas, Independence Blue Cross, Highmark Blue Cross Blue Shield, Blue Cross Blue Shield of Tennessee, and Government Employees Health Association/Federal Employees Program.
Guardant Health, Inc. (GH), announced that Palmetto GBA, a Medicare Administrative Contractor, has posted a draft local coverage determination (LCD) expanding Medicare coverage of the Guardant360® assay from advanced non-small cell lung cancer (NSCLC) to over a dozen advanced solid tumor cancer types with guideline-recommended genomic targets. The draft LCD would apply to advanced cancer patients who are covered by Medicare for next-generation sequencing of tumor tissue, but have insufficient or unavailable tissue samples. “This is an important step toward making sure all Medicare beneficiaries with advanced cancer have timely access to guideline-recommended treatment options,” said Guardant Health co-founder and CEO Helmy Eltoukhy, PhD.
Guardant Health, Inc. (GH), announced that it has entered into a definitive agreement to acquire Bellwether Bio, Inc., a privately held company focused on improving oncology patient care through their pioneering research into the epigenomic content of cell free DNA. The transaction is expected to close in April 2019. The Bellwether Bio team will join Guardant Health to further advance its early detection product pipeline. The team includes Jay Shendure, MD, PhD, who will act as a scientific advisor to Guardant Health.
On CNBC's "Mad Money Lightning Round" , Jim Cramer said that Guardant Health Inc (NASDAQ: GH ) is a winner. The acquisition of Red Hat is going to help IBM (NYSE: IBM ) greatly, said Cramer. ...
For the last quarter Guardant Health Inc reported a revenue of $32.9 million, compared with the revenue of $11.13 million during the same period a year ago. Warning! GuruFocus has detected 3 Warning Signs with GH. The Guardant Health Inc had an operating margin of -102.54%, compared with the operating margin of -153.71% a year before.
Diagnostics company Guardant Health has had an astronomical stock run this month on positive data for its cancer-treatment blood tests, known as G360, and a strong fourth-quarter report.
OUTSIDE THE BOX Here are four stocks to watch with strong price momentum fueled by earnings. Denali Therapeutics Inc. (DNLI) jumped $2.17 to $24.37 on 1.19 million shares Wednesday, nearly three times its average volume.
Stocks that moved substantially or traded heavily on Wednesday: Rite Aid Corp., up 4 cents to 72 cents The drugstore chain purged its top management, including CEO John Stanley, and said it will cut 400 ...
posted healthy gains on Wednesday after the company reported a fiscal fourth-quarter loss that was narrower than analysts' expectations. Guardant Health shares surged almost 14%, gaining $10.19 to $84.19 on the New York Stock Exchange, after the company said it lost $25.1 million, or 30 cents a share, in its most recent fiscal quarter, vs. a year-earlier loss of $15.1 million, or $1.27 a share. For 2019, Guardant Health said it expects full-year revenue in the range of $130 million to $135 million, though it also expects to record a loss in the range of $126 million to $129 million.
Apple, Microsoft and Google pushed the Nasdaq 100 index to a stock market rally high. Hot IPO Guardant Health rose on strong Q4 results.